US · MIRM
Mirum Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Foster City, CA 94404
- Website
- mirumpharma.com
Price · as of 2025-12-31
$96.53
Market cap 4.77B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $77.48 | -19.73% |
| Intrinsic Value(DCF) | $4,681.94 | +4,750.24% |
| Graham-Dodd Method(GD) | $3.94 | -95.92% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $16.06 | ||||
| 2020 | $19.86 | ||||
| 2021 | $21.75 | ||||
| 2022 | $22.30 | $45.87 | $0.00 | $0.00 | $0.00 |
| 2023 | $28.15 | $46.35 | $1.81 | $0.00 | $0.00 |
| 2024 | $43.46 | $65.87 | $176,258.72 | $0.00 | $0.00 |
| 2025 | $90.09 | $77.48 | $19,827.62 | $3.94 | $0.00 |
AI valuation
Our deep-learning model estimates Mirum Pharmaceuticals, Inc.'s (MIRM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $77.48
- Current price
- $96.53
- AI upside
- -19.73%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4,681.94
+4,750.24% upside
Graham-Dodd
$3.94
-95.92% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MIRM | Mirum Pharmaceuticals, In… | $96.53 | 4.77B | -20% | +4,750% | -96% | — | -193.57 | 14.37 | 8.67 | 259.00 | — | 84.11 | 80.71% | -4.25% | -4.48% | -8.65% | -8.65% | -3.09% | 1.01 | -1.54 | 2.67 | 2.46 | 1.20 | -7459.00% | 5474.00% | 48801.00% | 1.21% | 0.27 | 21.44% | 0.00% | 0.00% | 1.65% | -201.32 | 81.21 | 8.55 | 5.05 |
| ACAD | ACADIA Pharmaceuticals In… | $24.56 | 4.16B | +74% | +42% | -54% | +114% | 12.85 | 3.97 | 3.04 | 22.02 | — | 4.75 | 91.46% | 24.10% | 23.64% | 38.89% | 513.41% | 23.39% | 0.07 | — | 2.38 | 2.18 | -2.67 | -46757.00% | 3185.00% | -77327.00% | 5.40% | 0.40 | 398.52% | 0.00% | 0.00% | 4.68% | 9.56 | 14.03 | 2.30 | 3.24 |
| ADMA | ADMA Biologics, Inc. | $15.57 | 3.71B | +161% | +134% | -67% | +6% | 26.89 | 8.28 | 7.74 | 19.93 | — | 8.35 | 57.39% | 37.53% | 28.80% | 35.56% | 38.62% | 26.40% | 0.17 | 26.93 | 6.71 | 3.54 | -0.04 | -2593.00% | 1963.00% | -7473.00% | 0.70% | 0.72 | 6.98% | 0.00% | 0.00% | 0.81% | 20.60 | 141.74 | 7.73 | 18.36 |
| BLTE | Belite Bio, Inc | $190.30 | 6.64B | — | — | — | — | -53.39 | 13.23 | — | -50.05 | — | 13.61 | 0.00% | — | — | -30.60% | -1830.90% | -29.29% | 0.00 | -1999.80 | 24.31 | 24.09 | 0.87 | -84.00% | — | -172.00% | -1.52% | -4.83 | -1345.16% | 0.00% | 0.00% | 0.00% | -44.63 | -60.75 | — | 182.72 |
| DYN | Dyne Therapeutics, Inc. | $15.62 | 2.57B | — | — | — | — | -3.68 | 1.85 | — | -1.74 | — | 1.85 | 0.00% | — | — | -88.03% | -9599.05% | -74.14% | 0.04 | — | 15.60 | 15.20 | 1.31 | -1468.00% | — | 5604.00% | -25.25% | -6.92 | -8227.36% | 0.00% | 0.00% | 27.18% | -1.60 | -1.86 | — | 8.91 |
| LGND | Ligand Pharmaceuticals In… | $198.31 | 3.9B | +75% | -16% | -66% | +114% | 31.47 | 3.85 | 14.61 | 22.87 | — | 5.67 | 97.54% | 17.61% | 46.42% | 13.47% | 5.61% | 9.95% | 0.44 | -10.01 | 22.23 | 21.18 | -1.77 | -288636.00% | 6040.00% | -3682.00% | 1.25% | 1.32 | 7.43% | 0.00% | 0.00% | 5.54% | 77.01 | 74.32 | 13.56 | 5.21 |
| PRAX | Praxis Precision Medicine… | $336.75 | 7.12B | -61% | — | — | — | -24.53 | 8.47 | — | -22.57 | -76.60 | 8.47 | 0.00% | — | — | -45.83% | -195.82% | -42.68% | 0.00 | — | 10.22 | 10.03 | 1.18 | 3203.00% | -10000.00% | 8908.00% | -3.35% | -4.17 | -149.55% | 0.00% | 0.00% | 1.92% | -20.97 | -27.46 | — | 72.54 |
| RARE | Ultragenyx Pharmaceutical… | $23.39 | 2.26B | -15% | -61% | — | — | -3.95 | -28.37 | 3.37 | -5.71 | — | -7.57 | 83.80% | -79.49% | -85.44% | -656.03% | -567.31% | -37.89% | -15.95 | -8.63 | 2.48 | 2.22 | -1.68 | -731.00% | 2013.00% | 1193.00% | -20.80% | -1.21 | -500.50% | 0.00% | 0.00% | 0.00% | -5.33 | -6.04 | 4.24 | -3.56 |
| SLNO | Soleno Therapeutics, Inc. | $39.07 | 2.1B | — | -51% | -73% | — | 99.43 | 4.61 | 10.91 | 62.51 | — | 4.66 | 98.58% | 7.85% | 10.97% | 6.01% | 19.44% | 4.67% | 0.01 | 2.73 | 5.80 | 5.44 | -2.38 | -10890.00% | — | -16741.00% | 2.25% | 0.76 | 60.75% | 0.00% | 0.00% | 6.38% | 118.68 | 37.97 | 9.32 | 10.94 |
| TLX | Telix Pharmaceuticals Lim… | $7.25 | 2.43B | +233% | +1,741% | -93% | — | -340.42 | 5.85 | 3.02 | 52.73 | — | -13.68 | 53.11% | 2.21% | -0.89% | -1.80% | 3.26% | -0.65% | 1.26 | 0.48 | 1.43 | 1.21 | 7.16 | -12257.00% | 5391.00% | -38842.00% | -2.28% | -0.07 | -10.14% | 0.00% | 0.00% | 0.00% | 158.00 | -50.84 | 3.49 | 2.55 |
| TVTX | Travere Therapeutics, Inc… | $29.79 | 2.67B | +90% | +51,751% | — | — | -103.12 | 22.94 | 5.37 | 118.84 | — | 2744.19 | 85.51% | -12.80% | -10.24% | -29.38% | -59.63% | -4.26% | 2.86 | -5.85 | 2.74 | 2.52 | 10.61 | -8627.00% | 11045.00% | -11116.00% | 1.43% | 0.24 | 35.86% | 0.00% | 0.00% | 4.07% | -42.03 | 69.88 | 5.38 | 0.84 |
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
- CEO
- Christopher Peetz
- Employees
- 334
- Beta
- 0.50
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4,681.94 ÷ $96.53) − 1 = +4,750.24% (DCF, example).